Statins and the risk of colorectal cancer.

@article{Poynter2005StatinsAT,
  title={Statins and the risk of colorectal cancer.},
  author={Jenny N. Poynter and Stephen B. Gruber and Peter D. R. Higgins and Ronit Almog and Joseph D. Bonner and Hedy S. Rennert and Marcelo Low and Joel K. Greenson and Gadi Rennert},
  journal={The New England journal of medicine},
  year={2005},
  volume={352 21},
  pages={
          2184-92
        }
}
BACKGROUND Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase and effective lipid-lowering agents. Statins inhibit the growth of colon-cancer cell lines, and secondary analyses of some, but not all, clinical trials suggest that they reduce the risk of colorectal cancer. METHODS The Molecular Epidemiology of Colorectal Cancer study is a population-based case-control study of patients who received a diagnosis of colorectal cancer in northern Israel between 1998 and 2004… 

Tables from this paper

Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort.

The results do not support the hypothesis that statin use strongly reduces risk of colorectal cancer, but cannot rule out a small reduction in risk or an effect associated with only specific types or doses of statins.

The association between statins and cancer incidence in a veterans population.

Patients using statins may be at lower risk for developing cancer, and additional observational studies and randomized trials of statins for cancer prevention are warranted.

Statin use and risk of colorectal cancer.

Overall, use of statins did not appear to be associated with reduced risk of colorectal cancer, and the reducedrisk of stage IV cancer observed among statin users requires confirmation.

Statins and colorectal cancer

This paper attempts to bring together current knowledge/ evidence on statin therapy targeted at the development, disease course and treatment of colorectal cancer, both in terms of epidemiological findings and clinical observations.

Statin Use and Risk of Colorectal Cancer in a Cohort of Middle-Aged Men in the US

Findings provide little support for an association between the use of statins and the risk of colorectal cancer in men, and the possibility that this observation may be related to regular NSAID use cannot be ruled out.

The Impact of Statin Therapy on the Survival of Patients with Gastrointestinal Cancer.

This review summarizes the recent preclinical and clinical studies that assess the application of statins in the treatment of gastrointestinal cancers with particular emphasize on their association with cancer risk.

Statins and colorectal cancer.

  • P. LochheadA. Chan
  • Biology, Chemistry
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2013

Statin drugs and risk of advanced prostate cancer.

In this cohort of male health professionals, use of statin drugs was not associated with risk of prostate cancer overall but was associated with a reduced risk of advanced (especially metastatic or fatal) prostate cancer.

Statins and cancer risk.

...

References

SHOWING 1-10 OF 34 REFERENCES

The risk of cancer in users of statins.

It is suggested that statins may have a protective effect against cancer and are protective when used longer than 4 years or when more than 1350 defined daily doses are taken.

Reduced Risk of Colorectal Cancer among Long-Term Users of Aspirin and Nonaspirin Nonsteroidal Antiinflammatory Drugs

The data support the existence of an important protective effect of nonaspirin NSAID continuous intake against colorectal cancer and point to a similar reduction in risk for aspirin at doses of at least 300 mg daily.

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study.

The results of this study provide some degree of reassurance about the safety of HMG-CoA reductase inhibitors in the face of uncertainty about the long-term impact of these medications on cancer.

Safety of HMG-CoA Reductase Inhibitors: Focus on Atorvastatin

Atorvastatin is well tolerated in long-term treatment of dyslipidemia and is characterized by a safety profile similar to the other available statins.

A randomized trial of aspirin to prevent colorectal adenomas.

Low-dose aspirin has a moderate chemopreventive effect on adenomas in the large bowel, using generalized linear models to compute risk ratios and 95 percent confidence intervals.

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia

Treatment with pravastatin significantly reduced the incidence of myocardial infarction and death from cardiovascular causes without adversely affecting the risk of death from noncardiovascular causes in men with moderate hypercholesterolemia and no history of my Cardiac Infarction.